Tinzaparin Sodium

Summary

Tinzaparin Sodium (CHEMBL1201414) is an approved oligosaccharide (ATC B01AB10) targeting SERPINC1; indicated across 6 conditions including thrombotic disease and non-small cell lung carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Oligosaccharide
• ATC class: B01AB10
• Targets: 1 (SERPINC1)
• Indications: 6 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201414
Name	Tinzaparin Sodium
Type	Oligosaccharide
Max phase	4
ATC	B01AB10

Also known as: Innohep, LNH-1, LNH1, Logiparin, Tinzaparin na, Tinzaparin sodium, porcine, Tinzaparina de sodio, Tinzaparine sodique, TINZAPARIN SODIUM, TINZAPARINE

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SERPINC1	serpin family C member 1	Activation		0%	P01008

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): SERPINC1.

Top Reactome pathways

12 total, by targets touching each:

Pathway	Targets	Genes
Hemostasis	1	SERPINC1
R-HSA-140837	1	SERPINC1
R-HSA-140875	1	SERPINC1
R-HSA-140877	1	SERPINC1
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	1	SERPINC1
Metabolism of proteins	1	SERPINC1
Post-translational protein modification	1	SERPINC1
Post-translational protein phosphorylation	1	SERPINC1
Fibrin formation	1	SERPINC1
Initiation of coagulation cascade	1	SERPINC1
Regulation of clotting cascade	1	SERPINC1
Amplification and propagation of coagulation cascade	1	SERPINC1

Dominant GO biological processes

GO term	Targets
blood coagulation	1
regulation of blood coagulation	1
hemostasis	1

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
thrombotic disease	4	MONDO:0000831	HP:0004419

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
kidney cancer	1	MONDO:0002367	MONDO:0002367

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE4	4
PHASE3	2
PHASE2	2
PHASE2/PHASE3	1
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05735639	PHASE4	RECRUITING	THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
NCT00203580	PHASE4	COMPLETED	Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)
NCT00203658	PHASE4	COMPLETED	Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin
NCT01390051	PHASE4	COMPLETED	Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?
NCT00260988	PHASE2/PHASE3	COMPLETED	A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery
NCT03090880	PHASE3	TERMINATED	Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)
NCT05178628	PHASE3	UNKNOWN	The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer
NCT00061373	PHASE2	COMPLETED	Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
NCT00293501	PHASE1/PHASE2	UNKNOWN	Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery
NCT00981903	PHASE2	TERMINATED	Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
NCT00629447	Not specified	COMPLETED	Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

2 molecules share ≥1 primary target. Top 2 by shared-target count:

Molecule	Source	Status	Shared targets
IDRAPARINUX	ChEMBL	Phase 3	SERPINC1
fondaparinux	PubChem	Approved	SERPINC1